Neurocern Demonstrates $370M in Savings for Medicare and Health Insurance Using Artificial Intelligence and Data Analytics Targeted at Alzheimer’s Disease Drug Eligibility

(CHICAGO, IL) — Neurocern announced today a savings outcome of $370M over five years by leveraging artificial intelligence (AI) and neuroinformatics to guide patients to the right Alzheimer’s treatment at the right time. As new disease modifying treatments for Alzheimer’s disease continue to emerge, Medicare and private health insurance plans need data-driven methods to screen, identify, and guide patients to…

Understanding Neurological and Neuropsychological Assessments

When faced with a loved one who is experiencing new neurological symptoms, caregivers and other family members often don’t know who to turn to for their neurological concerns. Differentiating between specialists like neurologists and neuropsychologists can be confusing, and it can be hard to know what type of assessment is needed. When you or a loved one is facing a…